BioCentury
ARTICLE | Clinical News

3PO: Phase I started

June 9, 2014 7:00 AM UTC

Advanced Cancer Therapeutics began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV PFK-158, with a starting dose of 24 mg/m 2, in up to 48 patients with advanced solid tumors, includ...